BEYOND NEW HORIZONCANCERROP

About CancerROP

Genetics

Myongji Hospital

MJCELLBIOCancerROP

Clinical Application

AnalysisResearch/Diagnosis

Precision Cancer Treatment

Bench-to-Bedside

CANCERROP develops commercialized Molecular diagnostic products and provide genetic testing services

Early diagnosis Molecular

Diagnostics

Personalized

Medicine

Genetic Disorder

Diagnosis

Pathogen

GenomeWhole Genome

Sequencing

DNA Chip PCR NGS

Genome Information

The first CE approved BAC DNA Chip

Own 100,000 Human Genome Library

Start NGS service by securing its own DB

Optimal Infrastructure

R&D Production Infra Sales Network

• Own molecular diagnostic

Laboratory and research personnel

• Quality management System

- Korean Standard

→ KGMP, KFDA, Genetic Testing

- International Standards

→ ISO 9001, ISO 14001, ISO 13485

- EU Standards

- Size : 330 m2

- Capacity : 100,000/year

- Certificate : CE, GMP and FDA

- Etc : Class 10,000 Clean room,

Constant temperature and

humidity facility

• World #1 Production for BAC chip • Domestic and International

+Over 400 domestic OB/Gyn network

CancerROP overview

CANCERROP has 100,000 human genome libraries in Korea in order to make BAC DNA Chip

CANCERROP DNA Chip

• Collection of spotted DNA fragments from attached

to a slide glass

•Detecting the number of copies of chromosomes in

the genome at high resolution scale

DNA Chip

cDNA Chip

Olio DNA Chip

BAC DNA Chip

DNA Chip manufacturing process

DNA Purification

DNA Amplification

Completion of DNA

Chip

BAC DNA Library

END-Sequencing

Bioinformatics :

Homology

searching

15 pg →15 µg↑

CancerROP overview

CANCERROPMilestones

History & Vision

MGMED Launched2007

Molecular Genetic Research

Listed on KONEX (Korean New Exchange Stock Market)

2012

Listed on KOSDAQ (Korean Securities Dealer Association Quote)

2015

Corporate Name Change to CancerROP

Invest in Oxford Vacmedix (Solid Tumor Vaccines)

2017-2018

2019-

MJCELLBIO

Bio-medical Company Specialized in Cancer

Cell Immunotherapy (CAR-T, CAR-NK Cells)

Pipelines of CancerROP

Cancer TreatmentGenome

Analysis & DiagnosisOther Biz Area

• Personalized Selection of

Anticancer Drugs

• Oxford Vacmedix

- OVM Cancer Vaccines

• - Based on Recombinant

Overlapping Peptides (ROP)

• MJ CellBio

(CellI mmunotherapy)

• Microbiome

• Genomics Based on NGS

• Genomics Service/Gene

Library

• Medical Research

Organization

• Postmortem to Identify

Genetic Causes

• Attract Overseas Patients to

Korea

• Export of Precision Health

Products (Probiotics,

Cosmetics)

• Global Alliance

• Oxford Cancer Biomarkers

• DTC (Direct To Customer)

Genetic Testing –

Domestic/Foreign Markets

• Personalized Products Based

on Genomics – Cosmetics,

Vitamins

Innovative Molecular Diagnostics

Discovery

Development

Adoptive

Therapy

Data Base

Identification & Treatment

Obtain Big Data

【Hospital Platform】1

Genetic Analysis

【NGS Platform】2

Construction of Gene Library

Identify

Causes

Diagnosis

Development

Validation

/Treatment

Big Data

& Algorithm

Cancer Panel

• NGS of RNA / DNA

• Identify Cancer /Disease Driver Mutations

• Provide optimal treatment options against Cancer

Anti-Cancer Pipeline

Cancer Vaccine

OVM

Chimeric Antigen Receptor

MJCELLBIO

【Hospital Platform】

Myongji Hospital + MJCELLBIO

Personalized & Precision Medicine

On Site R&D and GMP facilities

Manufacture/Clinical Application

【NGS Platform】

Ⅱ. CANCERROP Business Area

MGmed CancerRop

As-Is Biz Expansion

2014 2015 2016

Government Grants(KRW 100 million won)

857 909 1128

# of Infertility treatment 76,273 84,358 87,155

Percentage of birth by infertility treatment

3.59% 4.36% 4.86%

Pregnancy & Birth-related Genetic Diagnosis Market

Prenatal Postnatal

Product M Chip G Chip

Market Size 20.5 Billion 35.5 Billion

Market FeatureAlternative

MarketGrowth Market

Market Share 2% 10%

#1 Market share in the field

Established Nationwide Sales network

Cancer Treatment1

Genome Analysis2

Other Biz Area3

• Secure the cancer treatment pipeline via Strategic

cooperation

- Prestige Bio(Targeted Tumor treatment), Oxford Vacmedix

(Cancer Vaccines), Oxford Cancer Biomarkers (biomarkers)

• NGS-based Genetic Diagnosis Service and Construction

of Gene Library

•DTC(Direct To Customer) Genetic Testing

- Provide customized healthcare products including

probiotics and cosmetics

• MRO / Global Medical Tourism

CancerROP Business Area

Oxford Vacmedix Cancer Vaccines OVM

1. ROP is taken up by specialantigen-presenting cells (APCs) and cleaved into peptides

2. MHC molecule in the APC presents the peptides to T cell receptors

The stimulated T cells attack tumors

ROP (Recombinant Overlapping Peptides)

- Significantly shortened product development

period

- Easy quality control and scalability as Single

clone Peptide

- Significant reduction of production time and

manufacturing cost

(More than 100 times cheaper)

Oxford Vacmedix Core Technology

Excellent scalability (applicable to other

carcinomas) and Flexibility

ROP

(Recombinant Overlapping Peptides )

- Cervical Cancer

- NSCLC

(Non-small

Lung Cancer)

- Ovarian Cancer

- Other Cancer

Therapeutic

VaccineDiagnostics

Adoptive Cell

Therapy

- Cervical Cancer

- Monitoring

Immunotherapy

-Chronic infection

- Latent Infection

- Cervical Cancer

- NSCLC

(Non-small

Lung Cancer)

- Ovarian Cancer

- Other Cancer

- Using recombinant overlapping peptide cross-sections,

including virus / bacterial or tumor antigens

- Stimulating cellular immunity (immunotherapy)

- All epitopes can be used regardless of patient's HLA

- Developed by Dr. Shisong Jiang (Harvard Univ.) & Oxford Univ.

- Vacmedix has an exclusive license of Harvard & Oxford Univ.

Significantly shortened product development period

Easy quality control and scalability as Single clone Peptide

Significant reduction of production time and

manufacturing cost (More than 100 times cheaper)

CANCER

-ROPR&D

MJ

Hospital

Interaction Interaction

Bench to Bedside

Oxford Vacmedix Cancer Vaccines OVM

OxfordCancer Biomarkers Cancer Biomarkers OCB

Commercialization of Cancer Biomarker

Founded by

World leading

authority Dr.

David Kerr

• OCB products

- ColoPredict : Probability of colorectal cancer occurrence

- ColoProg : Recurrence rate of colorectal cancer

- ColoTox : Diagnosis of colorectal cancer target cancer drug

efficacy & toxicity

- Professor of Cancer Medicine at Oxford University

- Founder of Celleron Therapeutics

- Chief Medical officer

- Founder of Cobra and Foundxsys found

- Official Medical advisor of Former British Prime Minister Tony Blair & David Cameron

CE Approved Medical Device

CanerRopMicroarray and NGS Genetic Testing

NIPT

Detect Chromosomal

error in all stages of

human life

With CancerRop’s

unique technology

platform

Test Criteria

Hair LossHair

thickness Pigmentation

AgingFirmnessVit.C

Metabolism

Blood

sugar

Caffeine

Metabolism Cholesterol

BMIBlood

PressureHDL/LDL

CanerRopMyDNA scanning

CancerRop’s DTC Brand

Integrated analysis of Genetic

and environmental factors

Customized data services

based on Big data

Guide for nutrition and life

style

DTC Genetic Testing

Sample collection

and receive

Test consent form

Genetic Test and

analysis

Analyze 48 genes extracted from

Saliva

and identified 12 physical

Characteristics

CancerRop: MJ Cellbio

Scientist, bluebirdbioPost-Doc, Washington University Ph. D. University of Texas at AustinB.S. at Korea University

Director

Director of New Horizon Research Center

Director of JW CreaGene

Scientist at Samsung Life Science

CEO & Founder

VP & CTO

Professor at Korea Univ.Adj. Professor at MD Anderson Cancer CenterPost-Doc, at Harvard Medical SchoolPh. D. at University of ChicagoB.S. at Seoul National Univ.

Professor, Department of Medical Oncology,

MD Anderson Cancer Center

Scientific AdvisorScientific Advisor

WangJun Lee, M.D.

Yoon Lee , Ph.D.

CassienYee, M.D.

BaeckSeung Lee, Ph.D.

KyungMi Lee , Ph.D.

Clinical Trials of

Immuno-Oncology

57.0

74 Billion

12 Billion

CellImmunotherapy

PA63

CAR-T The Ligand Has Higher Affinity than Antibody

to Tumor Antigen

*single-chain variable fragment (scFv)

scFv

recognizing

tumor antigen

PA63 ligand

recognizing

tumor antigen

Develop Next Generation CAR-T targeting

Solid Tumor

PA63 CAR-T

Technology Transfer

from Korea Univ.

Targeting Pancreatic

Cancer (1/10/2019)

2019 - 2020 2020 - 2021 2021 - 2025

POC Validation/ Development Phase I Phase II/III

Development of PA63 CAR-TCancerRop: MJ Cellbio Timeline

CEO & Founder

WangJun Lee

M.D., Ph.D. from Seoul National University

College of Medicine

Key Profile

Chairman of CancerROP

CEO and Founder of MJCELLBIO

Chairman of Myongji Hospital Foundation

President of Asia Oncolytic Virotherapy Association

Vice President of Gut Bio Society

Incheon SarangHospital

Cheong-punghoHospital

for elderly

Incheon SarangHospital

HaesongElderly Nursing Home

JecheonMyongjiHospital

MyongjiHospital

LGD annexed clinic

Myongji Medical Foundation

Goyangsi, Gyeonggi-doOpened in 1987 700 beds 140 doctors, 580 nurses, 1550 staffsAnnual performance for 2018: 600,000 outpatients, 200,000 inpatients

Myongji Hospital

Opened in March 2011180 beds and 528 staffs (28 doctors, 150 nurses, 350 staffs)Annual performance for 2018: 201,560 outpatients, 65,380 inpatients

Jecheon Myongji Hospital

Opened in 1998 350 beds and 767 staffs (65 doctors)Annual performance for 2018:370,000 outpatients, 100,000 inpatients

Incheon Sarang Hospital

1,600 Beds

2,700Staff

Incheon SarangMedical

Foundation

25%Growth

rate

MyongjiMedical

Foundation

$ 250MSales

375 MDs

Mayo ClinicCare Network

Educational Collaboration with Hanyang Univ.

Collaboration agreement (2018)

98 of MJ medical staffs have been appointed as professors

of at Hanyang University College of Medicine

Enrolled in MCCN

Clinical collaboration with Mayo Clinic for

medical information, e-consulting, e-tumor

board, health care

Sharing and advising clinical experience on

gene therapy and CAR-T cell therapy

Myongji Medical Foundation

Big Data from Patients

Clinical Unmet Needs

Target Patient Population

Clinical Benefit/ Risk

Clinical Study

Patient Centered Care

Diagnosis, Treatment

Patient FirstCell Therapy

ATC, NK Cell Therapy

CAR-T Immunotherapy

New Diagnostic

Genome-based

Personal Medicine

Molecular

Diagnostics

CancerRop’s vision

Hospital Centered Translational Medicine Hub

THANK YOU